Trastuzumab deruxtecan study for breast cancer patients
Treatments studied
Part of Cancer clinical trials.
This study looks at how well the drug trastuzumab deruxtecan works in women with breast cancer that has spread. It is for patients who have already taken this drug.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- Your breast cancer has spread to other parts of the body or cannot be removed with surgery.
- You have already received trastuzumab deruxtecan.
- Your medical records are available.
- You are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug for people with HER2-positive breast cancer that has spread to only a few places in the body (up to 5 spots). It aims to see if the treatment works well before starting stronger therapies.
This study follows women with advanced breast cancer (metastatic) who have hormone-receptor positive tumors and low HER2 levels, to see how well a new drug called Trastuzumab Deruxtecan works when used in routine clinical care after prior hormone therapy.
This trial tests a targeted antibody-drug medicine (trastuzumab deruxtecan, T-DXd) in people with metastatic breast cancer that is HER2-low or HER2 IHC 0. It may help by treating tumors that haven’t previously received anti-HER2 treatment in the metastatic setting.
This trial tests a targeted therapy called trastuzumab deruxtecan for people with advanced breast cancer. It aims to see how well the treatment works and how safe it is.
This study is testing a new drug called trastuzumab deruxtecan (also known as T-DXd) in women with advanced breast cancer that is hormone receptor positive and has a very low level of HER2 (called HER2-ultralow). The trial aims to see if this drug can help shrink or slow the growth of the cancer in this specific group of patients.
This study looks at how well the drug T-DXd (Enhertu) works against breast cancer that has spread or can't be removed with surgery. It includes patients with any level of HER2 protein, so it might be an option even if your cancer has low HER2.
Hear when a new HER2-positive Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.